SLC1A2 is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent de novo SLC1A2 missense variants cause a severe, early onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all 3 variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild-type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20-month-old SLC1A2-related epilepsy patient with the SLC1A2-modulating agent ceftriaxone did not result in a significant change in daily spasm count. ANN NEUROL 2019;85:921-926 G lutamate is the predominant central nervous system excitatory neurotransmitter, and its synaptic concentration is kept under tight control to prevent neuronal damage from excessive activation of glutamate receptors.
SLC1A2 is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent de novo SLC1A2 missense variants cause a severe, early onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all 3 variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild-type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20-month-old SLC1A2-related epilepsy patient with the SLC1A2-modulating agent ceftriaxone did not result in a significant change in daily spasm count. ANN NEUROL 2019; 85:921-926 G lutamate is the predominant central nervous system excitatory neurotransmitter, and its synaptic concentration is kept under tight control to prevent neuronal damage from excessive activation of glutamate receptors. 1, 2 Of the 5 glutamate transporters, the trimeric transporter SLC1A2 (also known at GLT-1 and EAAT2) and SLC1A3 mediate the bulk of glutamate clearance from the synaptic cleft via their expression in astrocytes. Pan-knockout or astrocyte-specific knockout of Slc1a2 in mice results in neuronal excitotoxicity, epilepsy, and premature death. 3, 4 Despite the severe epilepsy phenotype of homozygous Slc1a2 knockout mice, mice heterozygous for the Slc1a2 deletion demonstrate no apparent clinical phenotype. 3 Furthermore, heterozygous deletion of SLC1A2 in humans (as is frequently seen in the WAGR deletion syndrome) is only rarely associated with epilepsy. 5 In contrast to individuals with heterozygous SLC1A2 deletions, 3 heterozygous SLC1A2 missense variants have recently been implicated in severe early onset epilepsy (Online Mendelian Inheritance in Man database: #617105). [6] [7] [8] The mechanism by which these SLC1A2 missense variants cause epilepsy remains unclear, significantly hindering the ability to apply glutamate and SLC1A2-modulating therapies to treat these patients. 
Patients and Methods

Ceftriaxone Trial
An innovative therapy protocol was approved by the Boston Children's Hospital Institutional Review Board (IRB). After observing baseline epileptic spasm frequency via both caregiver-observed spasm count and continuous videoelectroencephalography (EEG) for 24 hours, intravenous (IV) ceftriaxone was initiated at 80mg/kg/day. The patient was observed for 2 days after ceftriaxone initiation with continuous video-EEG, then discharged after placement of a peripherally inserted central catheter for home ceftriaxone infusion. On days 7 and 14 of ceftriaxone therapy, she was admitted for planned monitoring of spasm counts using continuous video-EEG. Per the IRB protocol, treatment was stopped after 14 days of ceftriaxone therapy. Daily spasm counts were collected by the caregiver during treatment and for 12 days after ceftriaxone discontinuation.
Results
Clinical Spectrum of SLC1A2-Related Epilepsy
We present an expanded clinical phenotype of SLC1A2-related epilepsy based on 7 independent cases, including 1 new de novo dominant case, 5 previously reported de novo dominant cases, 6-8 and 1 previously reported recessive case.
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All 6 de novo dominant cases developed early onset epilepsy with symptom onset between 2 days and 6 weeks of life (Supplementary Table) . Seizures typically presented as focal motor events (often tonic or myoclonic), and progressed to multiple seizure types including epileptic spasms, myoclonic seizures, focal and generalized tonic seizures, and tonic-clonic seizures. Seizures were systematically refractory to multiple medications. Brain magnetic resonance imaging was normal for the first several months of life, but around 5 months of life began to show evidence of delayed myelination, thinning of the corpus callosum, and cerebral cortical atrophy. EEG patterns demonstrated multifocal and generalized epileptiform discharges with abnormal background activity, including modified and classic hypsarrhythmia. Common clinical features included severe global developmental delay (6/6 cases), cortical visual impairment (3/6 cases), axial hypotonia (6/6 cases), spasticity and/or joint contractures (5/6 cases), and kyphoscoliosis (2/6 cases). Of note, the case of recessive SLC1A2-related epilepsy appears milder, with seizure onset at 2 years of age that was controlled with a single medication and mild developmental delay.
Recurrent De Novo SLC1A2-Related Epilepsy Variants Localize to the Trimerization Domain of SLC1A2 Five of the 6 de novo dominant cases result from recurrent alterations at SLC1A2 Gly82 (Gly82Arg) and Leu85 (Leu85Pro), whereas Pro289Arg has only been observed in 1 case. All 3 of these amino acids are highly conserved and colocalize within the same region of the SLC1A2 trimerization domain, far from the glutamate binding site (Fig 1) . Both Gly82 and Leu85 are located in a close helix-helix contact between transmembrane helix (TMH) 2 and 5, whereas Pro289 is required to create a kink in TMH5. All 3 of these variants are predicted to disrupt TMH2 or TMH5.
Leu85Pro Variant Significantly Reduced SLC1A2 Activity To evaluate the effects of these de novo dominant variants on SLC1A2 function, we studied the Leu85Pro variant in a well-established in vitro model of transiently expressed SLC1A2 in HEK cells. 10 Both wild-type (WT) SLC1A2
(SLC1A2 wt ) and Leu85Pro SLC1A2 (SLC1A2 L85P ) proteins were readily expressed in HEK cells and were able to form trimeric plasma membrane-bound proteins (Fig 2) . However, compared to SLC1A2 wt , SLC1A2 L85P formed less monomeric (37 AE 9.4% of WT) and trimeric (47 AE 8.9% of WT) plasma membrane-bound SLC1A2 protein, yet maintained a preserved trimer-to-monomer ratio. acts in a dominant negative manner to reduce, but not eliminate, SLC1A2 wt glutamate transporter function. The dominant negative effect of SLC1A2 L85P on SLC1A2 wt function is likely mediated via an effect on SLC1A2 folding, trafficking, or functional disruption of mixed trimeric proteins, given the ability of SLC1A2 L85P to form stable trimeric protein.
Effect of Ceftriaxone on Seizure Frequency in a Patient with SLC1A2-Related Epilepsy
Given our observation in vitro that transfection with an increasing amount of both SLC1A2 wt and SLC1A2 L85P resulted in increased SLC1A2 function (see Fig 2F) , we hypothesized that increasing both SLC1A2 L85P and SLC1A2 wt expression in vivo may help partially alleviate the glutamate transporter defect caused by SLC1A2 L85P . To test this, we evaluated the SLC1A2-modulating agent ceftriaxone on a 20-month-old with de novo dominant Leu85Pro SLC1A2-related epilepsy. Ceftriaxone is an US Food and Drug Administration-approved antibiotic that crosses the blood-brain barrier and increases SLC1A2 expression and function within several days in neural tissue. [11] [12] [13] [14] [15] After IRB approval, the patient was initiated on IV ceftriaxone at 80mg/kg/day for 14 days. Caregiver-assessed daily spasms counts were recorded for 28 days and demonstrated good agreement with continuous video-EEG monitoring (Fig 3) . Ceftriaxone therapy did not result in a significant change in the daily spasm count (median 50 with vs 45 without ceftriaxone; p = 0.23, 2-tailed Welch t test; see Fig 3) , although subjectively the caregiver thought that the patient's overall level of alertness improved during ceftriaxone therapy. EEG background was unchanged, and treatment was not associated with any major adverse events. Overall, these findings indicate that the SLC1A2-modulating agent ceftriaxone did not improve daily epileptic spasm frequency over the short term in a 20-month-old with Leu85Pro SLC1A2-related epilepsy.
Discussion
We demonstrate that the recurrent de novo Leu85Pro SLC1A2 variant causes a severe, early onset developmental and epileptic encephalopathy via a dominant negative mechanism that reduces, but does not eliminate, SLC1A2 wt protein localization and function. Based on these findings, as well as the lack of seizures in humans and mice with heterozygous SLC1A2 loss-of-function variants, it appears that there is a critical dosage of functional SLC1A2 protein (somewhere between 0 and 50% of WT) under which seizures develop. It is possible that the differences in seizure severity between the dominant and recessive forms of this condition (see Supplementary Table) result from differences in the amount of remaining functional SLC1A2 protein, with the recessive variants resulting in a higher amount of remaining functional SLC1A2 protein. Finally, although ceftriaxone is one of the best studied SLC1A2-modulating agents across mice and humans, our report represents the first trial of ceftriaxone in a human with a condition resulting from a direct alteration in SLC1A2. Although we observed no benefit of a 2-week trial of ceftriaxone in this patient, additional studies are warranted. It is likely, based on progressive neuroimaging abnormalities in this disorder, that there is cumulative neuronal damage over time from excessive activation of glutamate receptors. As such, earlier initiation of SLC1A2-modulating agents may be efficacious to overcome the cumulative dominant negative effects of the variant SLC1A2 allele. We thank T. Lochner and Y. Amrein for their dedication and technical contribution as well as all the patients and families described in this case series. 
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